Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022

BUY
$39.79 - $70.31 $187,609 - $331,511
4,715 New
4,715 $225,000
Q2 2022

Aug 16, 2022

SELL
$29.86 - $62.36 $128,816 - $269,021
-4,314 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $8,972 - $13,720
167 Added 4.03%
4,314 $247,000
Q4 2021

Feb 09, 2022

BUY
$68.02 - $99.06 $1,972 - $2,872
29 Added 0.7%
4,147 $330,000
Q3 2021

Nov 12, 2021

SELL
$84.37 - $133.6 $2,109 - $3,340
-25 Reduced 0.6%
4,118 $358,000
Q2 2021

Aug 16, 2021

BUY
$64.12 - $128.71 $69,634 - $139,779
1,086 Added 35.53%
4,143 $533,000
Q1 2021

May 14, 2021

SELL
$71.28 - $120.75 $119,964 - $203,222
-1,683 Reduced 35.51%
3,057 $245,000
Q4 2020

Feb 16, 2021

BUY
$22.24 - $95.63 $105,417 - $453,286
4,740 New
4,740 $387,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.